Cost-effectiveness analysis of physical activity interventions for people with schizophrenia or bipolar disorder: systematic review.
Physical activity
bipolar affective disorders
cost-effectiveness
schizophrenia
systematic review
Journal
The British journal of psychiatry : the journal of mental science
ISSN: 1472-1465
Titre abrégé: Br J Psychiatry
Pays: England
ID NLM: 0342367
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
medline:
9
8
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
Clinical guidelines recommend providing physical activity interventions (PAIs) to people with schizophrenia or bipolar disorder for weight management. However, the cost-effectiveness of PAIs is unknown. To evaluate the availability and methodological quality of economic evaluations of PAIs for people with schizophrenia or bipolar disorder. Four databases (MEDLINE, Embase, PsycInfo and Scopus) were searched on 5 July 2022. Based on the retrieved studies, forward and backward citation searches were conducted. Two reviewers independently selected studies for inclusion. Study quality was assessed using the Drummond checklist. Review results were presented using narrative synthesis. Fourteen articles reporting nine studies were included. All included studies assessed PAIs within a multicomponent lifestyle intervention. Mixed findings were reported on the cost-effectiveness of multicomponent lifestyle intervention: three studies reported it as cost-effective; four studies reported it as not cost-effective; and two studies did not conclude whether it was cost-effective or not. Very limited evidence suggests that certain patient subgroups might be more likely to benefit from multicomponent lifestyle interventions with a PAI component: men; individuals with comorbid type 2 diabetes; and individuals who have been psychiatric hospital in-patients for ≥1 year. The quality of included studies ranged from moderate to high. The current economic evidence suggests that not all modalities of multicomponent lifestyle intervention including a PAI component are cost-effective for people with schizophrenia or bipolar disorder; and not all people with schizophrenia or bipolar disorder would benefit equally from the intervention. Future research is urgently needed to identify the cost-effective modality of PAI for different patient subgroups.
Sections du résumé
BACKGROUND
Clinical guidelines recommend providing physical activity interventions (PAIs) to people with schizophrenia or bipolar disorder for weight management. However, the cost-effectiveness of PAIs is unknown.
AIMS
To evaluate the availability and methodological quality of economic evaluations of PAIs for people with schizophrenia or bipolar disorder.
METHOD
Four databases (MEDLINE, Embase, PsycInfo and Scopus) were searched on 5 July 2022. Based on the retrieved studies, forward and backward citation searches were conducted. Two reviewers independently selected studies for inclusion. Study quality was assessed using the Drummond checklist. Review results were presented using narrative synthesis.
RESULTS
Fourteen articles reporting nine studies were included. All included studies assessed PAIs within a multicomponent lifestyle intervention. Mixed findings were reported on the cost-effectiveness of multicomponent lifestyle intervention: three studies reported it as cost-effective; four studies reported it as not cost-effective; and two studies did not conclude whether it was cost-effective or not. Very limited evidence suggests that certain patient subgroups might be more likely to benefit from multicomponent lifestyle interventions with a PAI component: men; individuals with comorbid type 2 diabetes; and individuals who have been psychiatric hospital in-patients for ≥1 year. The quality of included studies ranged from moderate to high.
CONCLUSIONS
The current economic evidence suggests that not all modalities of multicomponent lifestyle intervention including a PAI component are cost-effective for people with schizophrenia or bipolar disorder; and not all people with schizophrenia or bipolar disorder would benefit equally from the intervention. Future research is urgently needed to identify the cost-effective modality of PAI for different patient subgroups.
Identifiants
pubmed: 37526007
doi: 10.1192/bjp.2023.52
pii: S0007125023000521
pmc: PMC10405045
doi:
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
362-376Références
Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26
pubmed: 22009159
J Affect Disord. 2008 Sep;110(1-2):149-55
pubmed: 18234351
Int J Technol Assess Health Care. 2019;35(4):317-326
pubmed: 31328702
BMC Public Health. 2014 Aug 18;14:856
pubmed: 25134636
Health Technol Assess. 2016 Oct;20(79):1-150
pubmed: 27802843
Adm Policy Ment Health. 2016 Jul;43(4):604-15
pubmed: 26149243
Pharmacoeconomics. 2022 Feb;40(2):149-156
pubmed: 34713422
BMC Public Health. 2013 Jul 15;13:657
pubmed: 23855449
Cost Eff Resour Alloc. 2013 Feb 20;11(1):4
pubmed: 23425608
BMC Health Serv Res. 2022 Jan 5;22(1):27
pubmed: 34983508
Lancet Psychiatry. 2018 Feb;5(2):145-154
pubmed: 29396118
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Contemp Clin Trials. 2020 Oct;97:106143
pubmed: 32931919
Eur Arch Psychiatry Clin Neurosci. 2021 Mar;271(2):315-324
pubmed: 32748261
Health Technol Assess. 2016 Feb;20(14):1-192
pubmed: 26910256
Lancet Psychiatry. 2019 Aug;6(8):675-712
pubmed: 31324560
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
J Clin Epidemiol. 2021 Jan;129:138-150
pubmed: 32980429
Front Endocrinol (Lausanne). 2021 Nov 25;12:769309
pubmed: 34899604
Health Soc Care Community. 2022 Jul;30(4):e1048-e1060
pubmed: 34260782
BMC Psychiatry. 2017 Dec 22;17(1):407
pubmed: 29273021
Pharmacoeconomics. 2020 Jun;38(6):537-555
pubmed: 32144726
Glob Reg Health Technol Assess. 2020 Dec 14;7:131-138
pubmed: 36627968
Int J Behav Nutr Phys Act. 2011 Apr 11;8:28
pubmed: 21481247
J Psychiatr Pract. 2005 Nov;11(6):379-88
pubmed: 16304506
Health Psychol. 2019 Aug;38(8):689-700
pubmed: 31368753
N Engl J Med. 2013 Apr 25;368(17):1594-602
pubmed: 23517118
Schizophr Res. 2019 Feb;204:360-367
pubmed: 30055884
Pharmacoeconomics. 2023 Feb;41(2):139-153
pubmed: 36404364
Soc Psychiatry Psychiatr Epidemiol. 2007 Oct;42(10):787-93
pubmed: 17721669
Transl Behav Med. 2015 Sep;5(3):269-76
pubmed: 26327932
Br J Psychiatry. 2019 Feb;214(2):63-73
pubmed: 30251622
J Phys Act Health. 2019 May 1;16(5):380-383
pubmed: 30925847
BMC Public Health. 2013 Aug 29;13:787
pubmed: 23988266
Obesity (Silver Spring). 2017 Jun;25(6):1006-1013
pubmed: 28398006
Lancet Diabetes Endocrinol. 2018 Dec;6(12):944-953
pubmed: 30389323
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
BMC Psychiatry. 2013 Sep 28;13:238
pubmed: 24074269
BMC Psychiatry. 2019 Nov 5;19(1):339
pubmed: 31690281
Schizophr Res. 2021 Feb;228:134-144
pubmed: 33434727
PLoS One. 2020 Jul 10;15(7):e0234996
pubmed: 32649663
Lakartidningen. 2013 Sep 4-10;110(36):1539-41
pubmed: 24163907
J Consult Clin Psychol. 1982 Jun;50(3):448-9
pubmed: 6808042
EClinicalMedicine. 2022 Jul 14;51:101563
pubmed: 35860453